Health IT, Hospitals

FirstHealth of the Carolinas will use HealthMyne platform to improve lung cancer screening

Founded in 2013 and based in Madison, Wisconsin, HealthMyne offers a quantitative imaging decision support platform for radiology and oncology.

Healthcare provider network FirstHealth of the Carolinas will implement a solution from HealthMyne, a Madison, Wisconsin-based company offering a quantitative imaging decision support platform for radiology and oncology.

FirstHealth, which is based in Pinehurst, North Carolina, will use HealthMyne’s tool to advance its lung cancer screening program.

Dr. Michael Pritchett, a pulmonary specialist at Pinehurst Medical Clinic and the director of the Chest Center of the Carolinas at FirstHealth, commented in a statement:

With HealthMyne, we will now be able to screen more patients and improve tracking and follow-up. We will also have access to more accurate information that will help us make better clinical decisions. Our reporting and communications will also improve with HealthMyne as information is automatically and readily available to the entire care team.

Providers can use HealthMyne’s cancer screening module to track and report on patients who are at risk of developing cancer. The platform can also track lesions, help determine whether patients are eligible for screening, inform clinicians when patients need follow-up and send notifications of biopsy and lab results.

Additionally, FirstHealth will use the HealthMyne solution to streamline preparation of patients in their multidisciplinary thoracic oncology conferences. The Wisconsin company’s tumor conference module allows clinicians to increase the number of patients that benefit from the knowledge shared in tumor conferences.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Going forward, FirstHealth plans to use HealthMyne to pinpoint lung nodules found during other imaging studies outside of lung cancer screening. It will also use HealthMyne’s therapy response module to assess patients’ responses to treatment in clinical trials.

Founded in 2013, HealthMyne also secured a $15 million Series B funding round last August. Ascension Ventures led it while existing investors 4490 Ventures, WARF and Venture Investors also participated. The Wisconsin company said it planned to use the money to expand its commercialization efforts.

Photo: blueringmedia, Getty Images